Biopharma merger and acquisition value for the fourth quarter of 2024 reached $9.4bn from 34 transactions, 15 of which had disclosed values. At the top was H. Lundbeck’s $2.6bn purchase of publicly tr
“We’re at an exciting juncture in medicine where the perceived scientific boundaries in treatment across therapeutic areas continue to dissolve.” These words from Jeffrey Jones , chief medical office
A slower-than-usual year for medtech M&A in 2023 was reflected in relatively few company exits from the Top 100 annual listing of publicly traded device, diagnostics and healthtech companies by re
The reinvention of Baxter goes on. The company that in the early 2000s was a permanent fixture among the global top 10 medtechs, focused on peritoneal and hemodialysis, will transform further in 2025